Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial.

Date publication

août 2025

Journal

The Lancet. Haematology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr RUBIO Marie Thérèse , Dr D'AVENI-PINEY Maud

Tous les auteurs :
Robin M, D'Aveni M, Stamatoullas A, Raffoux E, Chevallier P, Garnier A, Mediavilla C, Carre M, Himberlin C, Sébert M, Ravinet A, Desseaux K, Labussière H, Alani M, Rubio MT, Huynh A, Adès L, de Latour RP, Paul F, Chermat F, Petit R, Mokeddem C, Charbonnier A, Thépot S, Chevret S, Fenaux P,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40784355

Résumé

The combination of a hypomethylating agent with donor lymphocyte infusion as maintenance therapy after haematopoietic stem-cell transplantation (HSCT) in acute myeloid leukaemia and myelodysplastic syndrome might reduce the risk of relapse. We aimed to evaluate the activity and safety of oral decitabine and cedazuridine (ASTX727) as maintenance after allogeneic HSCT in patients with acute myeloid leukaemia or myelodysplastic syndrome at very high risk of relapse post-transplantation.

Référence

Lancet Haematol. 2025 08 7;: